Melike Uysal
Melike Uysal has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Selma Tural Hesapcioglu
Department of Child and Adolescent Psychiatry, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Türkiye
3 shared publications - Dilan Aydin Ayva
Ankara Yildirim Beyazit University Yenimahalle Education and Research Hospital
2 shared publications Mehmet Fatih Ceylan
Department of Child and Adolescent Psychiatry, Ankara Yıldırım Beyazıt University Yenimahalle Research and Training Hospital, Turkey
2 shared publications- Mehmet Fatih Ceylan
Department of Child and Adolescent Psychiatry, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Türkiye
2 shared publications - Meliha Ceren Erkul
YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication Selma Tural Hesapçıoğlu
Department of Child and Adolescent Psychiatry, Ankara Yıldırım Beyazıt University Yenimahalle Research and Training Hospital, Ankara, Turkey
1 shared publication
Latest Publications
The Clinician–Parent Paradox in Sharenting: Professional Responsibility, Parental Autonomy, and Children's Digital Vulnerability
Sharenting—the practice of parents sharing children's personal data and images on digital platforms—has become increasingly normalized, raising concerns about privacy, safety, and psychological well‐being. While existing literature emphasizes the role of healthcare professionals in guiding families on digital risks, less attention has been paid to how clinicians themselves navigate these practices as parents. This paper introduces the concept of the “clinician–parent paradox in sharenting,” describing situations in which professional guidance on children's digital safety coexists with personal online practices that may contribute to children's digital exposure. We further propose the notion of a “digital credibility shield,” whereby professional identity may generate a perceived sense of control and attenuate risk perception in personal digital behaviour. Drawing on ethical considerations related to autonomy, professional responsibility, and the child's right to an open future, we argue that this paradox reflects a broader tension between expertise and everyday practice in digital environments. Conceptualizing this phenomenon may support ethical self‐reflection among healthcare professionals and provide a foundation for future empirical and normative research on digital parenting in clinical contexts.
The Clinician–Parent Paradox in Sharenting: Professional Responsibility, Parental Autonomy, and Children's Digital Vulnerability
Sharenting—the practice of parents sharing children's personal data and images on digital platforms—has become increasingly normalized, raising concerns about privacy, safety, and psychological well‐being. While existing literature emphasizes the role of healthcare professionals in guiding families on digital risks, less attention has been paid to how clinicians themselves navigate these practices as parents. This paper introduces the concept of the “clinician–parent paradox in sharenting,” describing situations in which professional guidance on children's digital safety coexists with personal online practices that may contribute to children's digital exposure. We further propose the notion of a “digital credibility shield,” whereby professional identity may generate a perceived sense of control and attenuate risk perception in personal digital behaviour. Drawing on ethical considerations related to autonomy, professional responsibility, and the child's right to an open future, we argue that this paradox reflects a broader tension between expertise and everyday practice in digital environments. Conceptualizing this phenomenon may support ethical self‐reflection among healthcare professionals and provide a foundation for future empirical and normative research on digital parenting in clinical contexts.
- 15 February 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (4) , 554-562
Clozapine treatment in adolescents with schizophrenia and autism spectrum disorder: Comparative clinical profiles and treatment outcomes from a retrospective study
Objective: Clozapine is a gold-standard antipsychotic for treatment-resistant schizophrenia, increasingly used off-label for severe autism spectrum disorder (ASD) with irritability or disruptive behaviors. This study evaluated clozapine’s efficacy and tolerability in children and adolescents with ASD or schizophrenia spectrum disorders (SSDs). Methods: A retrospective review of 26 inpatients (ASD: n = 8; SSD: n = 18) treated with clozapine included demographics, dosing, and hospitalization data. Symptom severity was assessed with the Clinical Global Impression-Severity Scale (CGI-S), Scale for the Assessment of Negative Symptoms (SANSs), Scale for the Assessment of Positive Symptoms (SAPSs), and Aberrant Behavior Checklist (ABC). Side effects were evaluated with the Ugvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale. Hematological parameters—white blood cells, neutrophils, lymphocytes, and neutrophil-to-lymphocyte ratio (NLR)—were compared pre-treatment and at 6 months. Results: Of the 26 patients, 50% had early-onset schizophrenia, 30.8% had ASD, and 19.2% had schizoaffective disorder. Clozapine was initiated at a mean age of 15.8 years, with a mean dose of 284.6 mg/day. Both SSD ( p < 0.001) and ASD ( p = 0.01) groups showed significant CGI improvement. SANS and SAPS improved in SSD ( p = 0.001, p < 0.001); ABC improved in ASD ( p = 0.012). UKU scores decreased in SSD ( p < 0.001) and trended downward in ASD ( p = 0.38). Hypersalivation (61.5%), increased appetite (53.8%), and sedation (34.6%) were common; no discontinuations occurred. Neutrophils increased ( p = 0.007), and lymphocytes decreased ( p = 0.037), with significant NLR elevation in SSD ( p = 0.006). Conclusion: Clozapine demonstrated strong efficacy and improved tolerability, reducing side effects compared to prior polypharmacy in refractory pediatric ASD and SSD.
- 15 February 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (4) , 554-562
Clozapine treatment in adolescents with schizophrenia and autism spectrum disorder: Comparative clinical profiles and treatment outcomes from a retrospective study
Objective: Clozapine is a gold-standard antipsychotic for treatment-resistant schizophrenia, increasingly used off-label for severe autism spectrum disorder (ASD) with irritability or disruptive behaviors. This study evaluated clozapine’s efficacy and tolerability in children and adolescents with ASD or schizophrenia spectrum disorders (SSDs). Methods: A retrospective review of 26 inpatients (ASD: n = 8; SSD: n = 18) treated with clozapine included demographics, dosing, and hospitalization data. Symptom severity was assessed with the Clinical Global Impression-Severity Scale (CGI-S), Scale for the Assessment of Negative Symptoms (SANSs), Scale for the Assessment of Positive Symptoms (SAPSs), and Aberrant Behavior Checklist (ABC). Side effects were evaluated with the Ugvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale. Hematological parameters—white blood cells, neutrophils, lymphocytes, and neutrophil-to-lymphocyte ratio (NLR)—were compared pre-treatment and at 6 months. Results: Of the 26 patients, 50% had early-onset schizophrenia, 30.8% had ASD, and 19.2% had schizoaffective disorder. Clozapine was initiated at a mean age of 15.8 years, with a mean dose of 284.6 mg/day. Both SSD ( p < 0.001) and ASD ( p = 0.01) groups showed significant CGI improvement. SANS and SAPS improved in SSD ( p = 0.001, p < 0.001); ABC improved in ASD ( p = 0.012). UKU scores decreased in SSD ( p < 0.001) and trended downward in ASD ( p = 0.38). Hypersalivation (61.5%), increased appetite (53.8%), and sedation (34.6%) were common; no discontinuations occurred. Neutrophils increased ( p = 0.007), and lymphocytes decreased ( p = 0.037), with significant NLR elevation in SSD ( p = 0.006). Conclusion: Clozapine demonstrated strong efficacy and improved tolerability, reducing side effects compared to prior polypharmacy in refractory pediatric ASD and SSD.
- Open Access
- 20 May 2025
- Published by Archives of Current Medical Research in Archives of Current Medical Research
- Vol. 6 (2) , 152-156
VALPROIC ACID AS AN EFFECTIVE TREATMENT FOR SELF-INJURIOUS BEHAVIOR IN A PATIENT WITH WOLF-HIRSCHHORN SYNDROME: A CASE REPORT
Wolf-Hirschhorn Syndrome (WHS) is a neurodevelopmental disorder (NDD) characterized by a microdeletion, often accompanied by maladaptive behaviors. First-line medical treatment involves antipsychotics; however, when antipsychotics prove insufficient, treatment options become limited. In this case, it was aimed to demonstrate that valproic acid as monotherapy could eliminate maladaptive behaviors in a patient diagnosed with WHS accompanied by self-injurious behavior. A 10-year 4-month-old female patient with WHS exhibited intense self-injurious behaviors. When her demands were not met, she would bang her head against the wall with significant force, risking severe traumatic injury, and bite her hand. She had previously received sufficient dosage and durations of aripiprazole and risperidone treatments without benefit. Valproic acid was initiated at a dose of 400 mg/day in divided doses. After the first month of treatment, the patient ceased the behavior of banging her head. Additionally, the behavior of biting her hand significantly decreased. The Aberrant Behavior Checklist (ABC) score, initially assessed at 51 points, decreased to 28 points after the first month of treatment. The decrease in the ABC score was particularly marked in the subscales of irritability and social withdrawal. This outcome suggests that in patients diagnosed with neurodevelopmental disorders (NDD) where antipsychotics have failed, valproic acid as a mood stabilizer may be beneficial as monotherapy in reducing self-injurious behavior.
- 20 May 2025
- Published by Archives of Current Medical Research in Archives of Current Medical Research
- Vol. 6 (2) , 152-156
Open AccessVALPROIC ACID AS AN EFFECTIVE TREATMENT FOR SELF-INJURIOUS BEHAVIOR IN A PATIENT WITH WOLF-HIRSCHHORN SYNDROME: A CASE REPORT
Wolf-Hirschhorn Syndrome (WHS) is a neurodevelopmental disorder (NDD) characterized by a microdeletion, often accompanied by maladaptive behaviors. First-line medical treatment involves antipsychotics; however, when antipsychotics prove insufficient, treatment options become limited. In this case, it was aimed to demonstrate that valproic acid as monotherapy could eliminate maladaptive behaviors in a patient diagnosed with WHS accompanied by self-injurious behavior. A 10-year 4-month-old female patient with WHS exhibited intense self-injurious behaviors. When her demands were not met, she would bang her head against the wall with significant force, risking severe traumatic injury, and bite her hand. She had previously received sufficient dosage and durations of aripiprazole and risperidone treatments without benefit. Valproic acid was initiated at a dose of 400 mg/day in divided doses. After the first month of treatment, the patient ceased the behavior of banging her head. Additionally, the behavior of biting her hand significantly decreased. The Aberrant Behavior Checklist (ABC) score, initially assessed at 51 points, decreased to 28 points after the first month of treatment. The decrease in the ABC score was particularly marked in the subscales of irritability and social withdrawal. This outcome suggests that in patients diagnosed with neurodevelopmental disorders (NDD) where antipsychotics have failed, valproic acid as a mood stabilizer may be beneficial as monotherapy in reducing self-injurious behavior.
- 25 November 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (1) , 1-7
Elevated neuron specific enolase levels in post-traumatic stress disorder
Neuron-specific enolase (NSE) is a biomarker indicative of neuronal cell damage. The aim of this study is to assess the NSE levels in patients diagnosed with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). Blood samples were collected from 43 individuals with PTSD (age range 11–17), 43 individuals with MDD (age range 10–17), and 40 age- and gender-matched healthy controls. The NSE levels were analyzed, and participants completed the Post-traumatic Stress Reaction Index, the Children’s Depression Inventory, and the Screen for Child Anxiety Related Disorders. Additionally, the Clinical Global Impressions Scale was filled out by the researcher. Results indicated that the NSE levels in the PTSD group were significantly higher than those in both the MDD group and the healthy control group. No significant difference in NSE levels was observed between the MDD group and the healthy control group. Conclusions: The findings suggest that elevated NSE levels in PTSD may be indicative of stress-related neuronal damage, distinguishing PTSD from MDD and healthy controls. These results underline the need for further research to explore the potential of NSE as a biomarker for PTSD and its implications for diagnosis and intervention strategies. What is Known: • Neuron-specific enolase (NSE) is a biomarker indicative of neuronal cell damage. • Elevated NSE levels have been observed in certain neuropsychiatric and neurological conditions, reflecting neuronal damage or stress. What is New: • NSE levels in adolescents with PTSD are significantly higher than those in both MDD patients and healthy controls, suggesting a specific association with trauma-related neuronal damage. • No significant difference in NSE levels was observed between MDD patients and healthy controls, highlighting the distinct neurobiological impact of trauma compared to depressive disorders.
- 25 November 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (1) , 1-7
Elevated neuron specific enolase levels in post-traumatic stress disorder
Neuron-specific enolase (NSE) is a biomarker indicative of neuronal cell damage. The aim of this study is to assess the NSE levels in patients diagnosed with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). Blood samples were collected from 43 individuals with PTSD (age range 11–17), 43 individuals with MDD (age range 10–17), and 40 age- and gender-matched healthy controls. The NSE levels were analyzed, and participants completed the Post-traumatic Stress Reaction Index, the Children’s Depression Inventory, and the Screen for Child Anxiety Related Disorders. Additionally, the Clinical Global Impressions Scale was filled out by the researcher. Results indicated that the NSE levels in the PTSD group were significantly higher than those in both the MDD group and the healthy control group. No significant difference in NSE levels was observed between the MDD group and the healthy control group. Conclusions: The findings suggest that elevated NSE levels in PTSD may be indicative of stress-related neuronal damage, distinguishing PTSD from MDD and healthy controls. These results underline the need for further research to explore the potential of NSE as a biomarker for PTSD and its implications for diagnosis and intervention strategies. What is Known: • Neuron-specific enolase (NSE) is a biomarker indicative of neuronal cell damage. • Elevated NSE levels have been observed in certain neuropsychiatric and neurological conditions, reflecting neuronal damage or stress. What is New: • NSE levels in adolescents with PTSD are significantly higher than those in both MDD patients and healthy controls, suggesting a specific association with trauma-related neuronal damage. • No significant difference in NSE levels was observed between MDD patients and healthy controls, highlighting the distinct neurobiological impact of trauma compared to depressive disorders.
- Open Access
- 30 June 2024
- Published by Medical Research Reports in Medical Research Reports
- Vol. 7 (2) , 88-101
Okul Öncesi Çocuklarda Özel Eğitim Etkinliğinin Değerlendirilmesi
Amaç: Çalışmanın amacı, özel eğitime yönlendirilen 2-7 yaş arası çocukların aldıkları eğitimlerin verimliliği değerlendirmektir. Bu sebeple çocukların tekrarlanan psikometrik testleri incelenmiş, eğitim öncesi ve sonrası testler arası farklılıklar belirlenmiştir. Ayrıca çocukların ve ailelerinin dosyalarında bulunan sosyo-demografik veri formları sayesinde sosyo-demografik özelliklerinin de aldıkları eğitime etkisi değerlendirilmiştir. Yöntem: Şubat 2019-Ocak 2022 tarihleri arasında Çocuklar İçin Özel Gereksinim Raporu (ÇÖZGER) almak için hastanemize başvuran tüm 7 yaş ve altı çocukların sağlık kurulu raporu dosyaları geriye dönük olarak taranmıştır. Çocuklara, özel eğitime başlamadan önce ve tekrar rapor yenilemek için başvurduklarında gelişim basamaklarını değerlendirmek ve karşılaştırmak amacıyla Ankara Gelişim Tarama Envanteri (AGTE) uygulanmıştır. Bu araştırma kapsamında araştırmacılar tarafından oluşturulan sosyo-demografik, klinik ve eğitim özellikleri veri formu kullanılmıştır. Bulgular: Araştırmanın ilk bulgusu başvuran çocukların tekrarlanan AGTE alt ölçekleri ve bu alt ölçeklerin yüzdesel değişimleri arasında anlamlı fark bulunmamasıdır. Araştırmanın ikinci bulgusu olarak yüzdesel olarak değişim otizm spektrum bozukluğu (OSB) ve entelektüel yeti yitimi (EYY) tanıları ile tekrar incelendiğinde yüzdesel değişim açısından anlamlı fark görülmemiş olmakla beraber EYY tanısına sahip çocukların gelişimsel alt testlerinin her birinde olumlu gelişme gözlenmişken; OSB tanılı çocukların alt testlerinde ise gelişimsel açıdan gerileme belirlenmiştir.Sonuç: Çalışmanın sonucunda ardışık gelişim testleri açısından anlamlı bir fark bulunmaması sebebiyle özel eğitime ihtiyaç duyan bu çocukları sadece bir tanı özelinde değerlendirmek yerine her çocuğun sahip oldukları yetenekler ve desteğe ihtiyaç duyduğu alanlar açısından detaylıca değerlendirilip sonrasında en ideal eğitime yönlendirilmesi gerektiği düşüncesine varılmıştır.
- 30 June 2024
- Published by Medical Research Reports in Medical Research Reports
- Vol. 7 (2) , 88-101
Open AccessOkul Öncesi Çocuklarda Özel Eğitim Etkinliğinin Değerlendirilmesi
Amaç: Çalışmanın amacı, özel eğitime yönlendirilen 2-7 yaş arası çocukların aldıkları eğitimlerin verimliliği değerlendirmektir. Bu sebeple çocukların tekrarlanan psikometrik testleri incelenmiş, eğitim öncesi ve sonrası testler arası farklılıklar belirlenmiştir. Ayrıca çocukların ve ailelerinin dosyalarında bulunan sosyo-demografik veri formları sayesinde sosyo-demografik özelliklerinin de aldıkları eğitime etkisi değerlendirilmiştir. Yöntem: Şubat 2019-Ocak 2022 tarihleri arasında Çocuklar İçin Özel Gereksinim Raporu (ÇÖZGER) almak için hastanemize başvuran tüm 7 yaş ve altı çocukların sağlık kurulu raporu dosyaları geriye dönük olarak taranmıştır. Çocuklara, özel eğitime başlamadan önce ve tekrar rapor yenilemek için başvurduklarında gelişim basamaklarını değerlendirmek ve karşılaştırmak amacıyla Ankara Gelişim Tarama Envanteri (AGTE) uygulanmıştır. Bu araştırma kapsamında araştırmacılar tarafından oluşturulan sosyo-demografik, klinik ve eğitim özellikleri veri formu kullanılmıştır. Bulgular: Araştırmanın ilk bulgusu başvuran çocukların tekrarlanan AGTE alt ölçekleri ve bu alt ölçeklerin yüzdesel değişimleri arasında anlamlı fark bulunmamasıdır. Araştırmanın ikinci bulgusu olarak yüzdesel olarak değişim otizm spektrum bozukluğu (OSB) ve entelektüel yeti yitimi (EYY) tanıları ile tekrar incelendiğinde yüzdesel değişim açısından anlamlı fark görülmemiş olmakla beraber EYY tanısına sahip çocukların gelişimsel alt testlerinin her birinde olumlu gelişme gözlenmişken; OSB tanılı çocukların alt testlerinde ise gelişimsel açıdan gerileme belirlenmiştir.Sonuç: Çalışmanın sonucunda ardışık gelişim testleri açısından anlamlı bir fark bulunmaması sebebiyle özel eğitime ihtiyaç duyan bu çocukları sadece bir tanı özelinde değerlendirmek yerine her çocuğun sahip oldukları yetenekler ve desteğe ihtiyaç duyduğu alanlar açısından detaylıca değerlendirilip sonrasında en ideal eğitime yönlendirilmesi gerektiği düşüncesine varılmıştır.